2-氯-N-(3,4-二氯苯基)苯甲酰胺 | 7017-22-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氯-N-(3,4-二氯苯基)苯甲酰胺
• 英文名称: 2-Chlor-benzoesaeure-(3,4-dichlor-anilid)
• 英文别名: 2-chloro-benzoic acid-(3,4-dichloro-anilide)；2-chloro-N-(3,4-dichlorophenyl)benzamide
• CAS: 7017-22-3
• 化学式: C₁₃H₈Cl₃NO
• mdl: MFCD00590002
• 分子量: 300.572
• InChiKey: RQWZZMVBASVGGO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-氯-N-(3-氯苯基)苯甲酰胺 在 磺酰氯 、 苯 作用下， 生成 2-氯-N-(3,4-二氯苯基)苯甲酰胺
  参考文献：
  名称：

  Hirwe; Jadhav; Sukhtankar, Journal of the Indian Chemical Society, 1939, vol. 16, p. 281,284

  摘要：

  DOI：

文献信息

• BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS
  申请人：Galley Guido

  公开号：US20090036420A1

  公开（公告）日：2009-02-05

  The present invention relates to methods of treating CNS disorders with a compound of formula I wherein X, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are as defined in the specification and pharmaceutically acceptable acid addition salts thereof.

  本发明涉及使用式I中的化合物治疗中枢神经系统疾病的方法，其中X、R1、R2、R3、R4、R5、R6、R7和R8如说明书中所定义，并且包括药学上可接受的酸盐。
• Aliev,N.A. et al., Journal of general chemistry of the USSR, 1966, vol. 36, # 4, p. 653 - 654
  作者：Aliev,N.A. et al.

  DOI：——

  日期：——
• 2-AMINOBENZOTHIAZOLES AS CB1 RECEPTOR INVERSE AGONISTS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP1638556B1

  公开（公告）日：2008-04-02
• [EN] THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS<br/>[FR] UTILISATION DE DÉRIVÉS DE BENZAMIDE POUR LE TRAITEMENT DE TROUBLES DU SNC
  申请人：HOFFMANN LA ROCHE

  公开号：WO2009016088A1

  公开（公告）日：2009-02-05

  The present invention relates to the use of a compound of formula (I), wherein R or a pharmaceutically acceptable acid addition salt thereof, for the manufacture of a medicament for the treatment of CNS disorders selected from depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress- related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.